(-0.08%) 5 143.00 points
(-0.03%) 38 546 points
(-0.02%) 17 900 points
(-0.31%) $82.37
(1.33%) $2.06
(-1.09%) $2 332.10
(-2.28%) $27.03
(-0.60%) $955.70
(0.27%) $0.935
(0.52%) $11.04
(0.25%) $0.798
(-0.27%) $93.05
3.05% ¥ 2 690.00
Live Chart Being Loaded With Signals
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company...
Stats | |
---|---|
Tagesvolumen | 2.13M |
Durchschnittsvolumen | 3.84M |
Marktkapitalisierung | 3 984.93B |
EPS | ¥0 ( 2024-02-07 ) |
Nächstes Ertragsdatum | ( ¥17.50 ) 2024-05-13 |
Last Dividend | ¥21.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 40.41 |
ATR14 | ¥1.359 (0.05%) |
Volumen Korrelation
Terumo Corporation Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Terumo Corporation Korrelation - Währung/Rohstoff
Terumo Corporation Finanzdaten
Annual | 2022 |
Umsatz: | ¥820.21B |
Bruttogewinn: | ¥417.37B (50.89 %) |
EPS: | ¥59.50 |
FY | 2022 |
Umsatz: | ¥820.21B |
Bruttogewinn: | ¥417.37B (50.89 %) |
EPS: | ¥59.50 |
FY | 2022 |
Umsatz: | ¥703.30B |
Bruttogewinn: | ¥369.34B (52.52 %) |
EPS: | ¥117.45 |
FY | 2021 |
Umsatz: | ¥613.84B |
Bruttogewinn: | ¥326.62B (53.21 %) |
EPS: | ¥102.33 |
Financial Reports:
No articles found.
Terumo Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥19.00 (N/A) |
¥0 (N/A) |
¥21.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.063 | 2000-03-28 |
Last Dividend | ¥21.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥341.63 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.34 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.45 | |
Div. Directional Score | 9.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7949.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7182.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6420.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5401.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
4410.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3593.T | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
2811.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
1429.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9729.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8769.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.112 | 1.500 | 7.76 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0585 | 1.200 | 8.05 | 9.66 | [0 - 0.3] |
returnOnEquityTTM | 0.0827 | 1.500 | -0.192 | -0.288 | [0.1 - 1] |
payoutRatioTTM | 0.323 | -1.000 | 6.77 | -6.77 | [0 - 1] |
currentRatioTTM | 1.905 | 0.800 | 5.48 | 4.38 | [1 - 3] |
quickRatioTTM | 1.034 | 0.800 | 8.62 | 6.90 | [0.8 - 2.5] |
cashRatioTTM | 0.466 | 1.500 | 8.52 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.134 | -1.500 | 7.77 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 45.48 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 89.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 40.66 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.186 | -1.500 | 9.26 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.513 | 1.000 | 4.79 | 4.79 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.146 | 1.000 | 9.08 | 9.08 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.592 | 1.000 | 7.82 | 7.82 | [0.2 - 2] |
assetTurnoverTTM | 0.523 | 0.800 | 9.84 | 7.88 | [0.5 - 2] |
Total Score | 12.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.22 | 1.000 | 6.14 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0827 | 2.50 | -0.124 | -0.288 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 40.66 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.264 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 89.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.323 | 1.500 | 6.77 | -6.77 | [0 - 1] |
pegRatioTTM | 2.65 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.151 | 1.000 | 8.72 | 0 | [0.1 - 0.5] |
Total Score | 6.45 |
Terumo Corporation
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.